Results Among women with LSIL cytology, HPV16/18 positivity was 29.4 % and increased to 58.9 % for 8 types and to 74.8 % for 13 types (P < 0.001). The risk of CIN3+ biopsy results was still 7.9 % for women testing negative for HPV16/18, but decreased to 0.0 % for those testing negative for at least eight types of HPV (HPV16/18/31/33/35/45/52/58). Although HPV genotyping results enabled additional risk stratification among women with HSIL/ASC-H cytology, the risk of histological CIN3+ diagnosis among women testing negative for eight types or more was still sufficiently high (>35 %) to warrant immediate colposcopy referral. Conclusions Of women with LSIL cytology, those testing negative for at least eight of the highest-risk types of HPV (HPV16/18/31/33/35/45/52/58) may not need immediate colposcopy and biopsy. This would reduce the number of colposcopy referrals by approximately 40 %. However, the HPV genotyping assay is not likely to alter the clinical management of women with HSIL/ASC-H.
abnormalities [1] [2] [3] . In Japan, cervical intraepithelial neoplasia grade 3 (CIN3) is the standard threshold for immediate treatment [3] . The risk of CIN3 or worse (CIN3+) diagnosed at initial colposcopy and biopsy varies substantially, depending on referral cytology results. Among women with low-grade squamous intraepithelial lesion (LSIL) cytology, only 4-10 % are diagnosed with CIN3+ [4, 5] whereas 40-50 % of women with high-grade squamous intraepithelial lesion (HSIL) cytology have CIN3+ [6, 7] . In addition, the risk of CIN3+ is approximately 30 % for women with atypical squamous cells, cannot exclude HSIL (ASC-H) [8] . Referring these screen-positive women for colposcopy and histological examination is warranted to eliminate the possibility of CIN3+ lesions, but results in substantial costs for the health-care system and potential overtreatment of non-progressive lesions. In addition, taking of diagnostic biopsies during colposcopy can be painful. Therefore, a biomarker or molecular test that can provide additional information about the likelihood of CIN3+ lesions would have clinical benefits in avoiding unnecessary referrals for colposcopy.
Persistent infection with any of the 13 genotypes of carcinogenic human papillomavirus (HPV) (HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, and HPV68) can cause cervical cancer [9] . Thus, high-risk HPV testing for detection of the presence or absence of any of these 13 carcinogenic types is used in cervical cancer screening (usually as a co-test with cytology for women over 30 years of age) and as a triage test for women with atypical squamous cells of undetermined significance (ASC-US), because it is very useful for identifying women at increased risk of CIN2+ [1] . However, the risk of progression to cervical cancer and precancer varies substantially among individual carcinogenic genotypes [10] [11] [12] [13] . HPV16 and HPV18 are the two most common genotypes associated with invasive cervical cancer, with the eight major carcinogenic genotypes HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV52 and HPV58 accounting for >90 % of cases of cervical cancer throughout the world. To date, genotyping for two types (HPV16/18) and eight types (the 2 types + HPV31/33/35/45/52/58) has been incorporated into clinical guidelines for cervical cancer prevention [1, 3] . In current US guidelines, genotyping for HPV16, HPV18, or both, among high-risk HPV-positive women with normal cytology has been recommended as a triage test for identification of those at greatest risk of CIN2+ who warrant immediate colposcopy and biopsy [1] . In the clinical guidelines of the Japanese Society of Obstetrics and Gynecology (JSOG) and the Japan Association of Obstetricians and Gynecologists (JAOG), testing women with biopsy-positive CIN1/2 for the eight highest-risk types of HPV is recommended to assist in making a treatment decision for women with CIN2 or to decide follow-up intervals according to risk stratification of progression to CIN3+ [3] .
This prospective study was designed to assess potentially better algorithms for women with abnormal cervical screening results. To be useful for clinical management, risk stratification achieved by HPV genotyping should lead to different management decisions, for example immediate referral for colposcopy or repeated cytology (if necessary, delayed colposcopy). We examined whether testing screen-positive women for 2 types (HPV16/18), or the 8 major carcinogenic types, or all 13 of carcinogenic types can serve as a triage test to discriminate, on the basis of risk stratification, populations who do not need immediate colposcopy and biopsy.
Materials and methods

Study design
Between April 2010 and March 2012, 480 women referred for colposcopy and histological examination for abnormal cytology were enrolled in the study at four hospitals located in Tsukuba city and the neighboring areas: 300 women were recruited from the University of Tsukuba Hospital, 81 from Tsukuba Medical Center Hospital, 79 from Tsuchiura Kyodo General Hospital, and 20 from Ibaraki Prefectural Central Hospital. Retails of this study have been reported elsewhere [14] . Briefly, all subjects entered the study only after voluntarily giving signed informed consent. At study entry, gynecologists were asked to take at least three cervical specimens including by endocervical curettage (ECC). In addition, exfoliated cells from the ectocervix and endocervix were collected for HPV genotyping assays. Histological diagnosis was made on the basis of hematoxylin and eosin (HE)-stained sections in accordance with the World Health Organization (WHO) classification. Two pathologists (Y.M. and M.N.) reviewed all histological specimens; they were unaware of the cytology, HPV genotyping results, and clinical data obtained from the study subjects. When the pathologists' review results differed, final diagnosis was based on discussion between them. Cervical smears were classified according to the Bethesda System. Because of the relevance to clinical practice, we did not review cytological specimens that resulted in referral for colposcopy. We defined the worst histologic finding obtained from at least three cervical specimens as the final histologic diagnosis. To date, several studies have reported that the number of cervical biopsies obtained during colposcopy affects the diagnostic accuracy of colposcopic procedures [14, 15] . Therefore, 30 women for whom the number of biopsies was insufficient (<3) were excluded from the analysis because the worst lesions may have been missed. In addition, 23 women with ASC-US cytology were also excluded from the analysis, because of insufficient sample size for statistical analysis. Overall, the analysis cohort consisted of 427 women with LSIL, HSIL, or ASC-H cytology for whom at least three cervical specimens were histologically evaluated and tested for the 13 carcinogenic HPV genotypes.
The ethics committee of the Clinical Trial and Research Center of the University of Tsukuba Hospital approved the study protocol. The institutional ethical and research review boards of Tsukuba Medical Center Hospital, Tsuchiura Kyodo General Hospital, and Ibaraki Prefectural Central Hospital also approved the study protocol.
HPV detection and genotyping
We identified the HPV genotypes present in the cervical samples by use of the Clinichip HPV ® test (Sekisui Medical, Tokyo, Japan), a new DNA test that detects oncogenic HPVs rapidly by loop-mediated isothermal amplification (LAMP) and performs genotyping for all 13 oncogenic HPV types by use of automated DNA chip technology. The detection limit of the Clinichip HPV ® test is set as 1 × 10 2 copies/μL for each genotype. This assay is approved for clinical use by the Ministry of Health, Labour and Welfare in Japan, because of its high sensitivity and type-specificity. HPV detection and genotyping using the Clinichip HPV ® test has been described elsewhere [16] . In brief, exfoliated cells from the ectocervix and endocervix were collected in a tube containing 1 mL phosphatebuffered saline (PBS) and stored at −30 °C until DNA extraction. Total cellular DNA was extracted from 300 μL of a cervical sample with 120 μL elution buffer by use of a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany), in accordance with the manufacturer's recommended procedure. For the Clinichip HPV ® genotyping assay, total extracted DNA was incubated at 95 °C for 5 min. Then, 1 μL DNA (0.3 % of the total DNA from the original cervical sample) was added to each of six LAMP tubes by manual pipetting. Each tube contained 24 μL LAMP reagent and specific primers for the different HPV types. The tubes were incubated at 65 °C for 90 min to achieve target DNA amplification. The amplified products from each tube (10-μL) were then mixed with 6 μL hybridization buffer (saline-sodium citrate solution), and 50 μL of the mixed LAMP products were applied to the electrochemical DNA chip by manual pipetting. DNA chip analysis for HPV genotyping was performed automatically by use of a Genelyzer™ (Toshiba, Tokyo, Japan), an instrument which measures electrochemical signals from the chip. DNA probes for the target genes were fixed on the electrodes of the DNA chip by chemisorption by gold and sulfur. The amplified DNA sample was added to the chip and left to hybridize to the specific carcinogenic HPV probes. The positive control probe was designed on the basis of the sequence of the LAMP product for human β-globin. A negative control DNA probe was also designed with an arbitrary 25-base sequence unrelated to the sequences of HPV or other viruses and microbes known to exist in the uterine cervix. Current flows between the bound intercalator and the DNA chip electrode only when DNA in the sample binds to a specific probe on the DNA chip with the complementary sequence. The test was regarded as positive for an HPV type when the current obtained with the specific probe was at least 10 nA higher than that obtained with the negative control probe.
All of the HPV DNA assays were performed in the OB/ GYN laboratory of the University of Tsukuba Hospital by individuals who were unaware of the clinical profile of each subject.
Statistical analysis
Because women with ASC-H (viewed as equivocal HSIL) are, under current guidelines, managed with those with HSIL, the cytology results were divided into two groups: LSIL (n = 214) and HSIL/ASC-H (n = 213). In this study, we used the primary endpoint of CIN3 or worse because: 1 CIN3 is a more certain, rigorous histological diagnosis of precancer than CIN2; and 2 CIN3 is the standard threshold for immediate treatment in Japan [3] .
CIN2 is an equivocal diagnosis of precancer, and often regresses spontaneously [13, 17] . We examined different combinations of cytology and HPV genotyping for the 2 types, 8 types, or 13 types for triage for colposcopy for women with abnormal cervical screening results. The absolute risk of biopsy results for CIN3+ was calculated on the basis of cytological interpretation and HPV genotyping results. To estimate relative CIN3+ risk associated with HPV genotypes, odds ratios (OR) were calculated by use of contingency table analysis with the chi-squared test and Fisher's exact test. The sensitivity and specificity of type-specific HPV tests for predicting CIN3+ were also analyzed. All statistical analysis was performed by use of the JMP 10.0 J statistics package (SAS Institute, Cary, NC, USA). Two-sided P values were calculated throughout and considered to be significant at <0.05.
Results
One-hundred and forty-five women (34.0 % of all study subjects) were histologically diagnosed with CIN3+.
Although the mean age and numbers of cervical biopsies taken during colposcopy were similar for women with LSIL and HSIL/ASC-H, the absolute risk of prevalent CIN3+ was much higher among women with HSIL/ ASC-H than among those with LSIL (56.3 vs. 11.7 %, P < 0.0001, Table 1 ). In this study, all women diagnosed with invasive cancer had HSIL referral cytology.
Carcinogenic HPV DNA was detected for 84.8 % (362/427) of all study subjects. Carcinogenic HPV was detected for 74.8 % (160/214) of women with LSIL cytology and 91.1 % (194/213) of those with HSIL/ASC-H cytology (P < 0.0001). Infection by several types was detected for 34.0 % (123/362) of women positive for any carcinogenic HPV. Among all study subjects, HPV16 was the most common genotype (30.4 %), followed by HPV52 (23.2 %), HPV58 (16.4 %), HPV51 (13.1 %), HPV31 (8.0 %), and HPV18 (7.0 %). Among women diagnosed with CIN3+, HPV16 (44.8 %) was most frequently detected, followed by HPV52 (26.7 %), HPV58 (16.6 %), HPV31 (13.8 %), HPV51 (8.9 %), and HPV18 (7.6 %). In analysis confined to 304 women with a single infection, the relative risk of CIN3+ detection was the highest for HPV16 (OR 5.18, 95 % confidence interval (CI) 2.94-9.14), followed by HPV31 (OR 3.90, 95 % CI Among women referred for colposcopy for LSIL cytology, HPV16/18 positivity was 29.4 %; it increased to 58.9 % for the 8 types and to 74.8 % for the 13 types (P < 0.001) ( Table 3) . We examined the absolute and relative risks of histological CIN3+ diagnosis when test results were positive or negative for each of the 2 types, 8 types, and 13 types. Risk discrimination between test-positives and test-negatives was statistically significant for testing for the 2 types (P = 0.01), 8 types (P < 0.0001), or 13 types (P < 0.0001) ( Table 3 ). HPV16/18-positive women were at three times greater risk of CIN3+ histology than were HPV16/18-negative women (OR 3.01, 95 % CI 1.29-7.04). However, the absolute risk of CIN3+ biopsy results was still high (7.9 %, 95 % CI 4.6-12.4) for women testing negative for HPV16/18 ( Fig. 1) , suggesting that women testing negative for HPV16/18 would still need immediate colposcopy referral. However, the absolute CIN3+ risk decreased to 0.0 % for those testing negative for at least the eight types HPV16/18/31/33/35/45/52/58. This suggests that LSIL cases negative for at least these eight types may not need immediate colposcopy and biopsy. Because 41.1 % of women with LSIL were negative for the eight types, our data suggest that testing women with LSIL cytology for the eight types would reduce the number of colposcopy referrals by approximately 40 %. Similarly, women negative for all 13 carcinogenic HPVs were at very low risk (0.0 %, 95 % CI 0.0-4.2) of CIN3+ histology (Fig. 1) , although the high prevalence (74.8 %) of the 13 carcinogenic HPVs among women with LSIL suggested that testing for 13 carcinogenic HPVs as a triage test would send as many as 70-80 % of women with LSIL for colposcopy. Among the women who underwent colposcopy and biopsy for HSIL/ASC-H cytology, addition of type-specific HPV testing also characterized the risk of biopsy results for CIN3+ more precisely (Fig. 1) . Risk discrimination between test-positive and test-negative women was statistically significant for testing for the two types (OR 2.13, 95 % CI 1.22-3.74, P = 0.01) or eight types (OR 2.31, 95 % CI 1.06-5.05, P = 0.03) (Table 3) . However, the absolute risk of histological CIN3+ diagnosis among women testing negative for the 2 types, the 8 types, or even the 13 types was still sufficiently high (>35 %) to warrant immediate colposcopy referral.
Discussion
In cytology-based cervical screening programs, women with abnormal cytology are referred for colposcopic examination for histologic evaluation of cervical abnormalities [1] [2] [3] . In screening practices, all of the diagnostic tools cytology, colposcopy, and histology are essential for accurate diagnosis of cervical cancer and precancer. Currently, colposcopy examination and biopsy results determine how screen-positive women are managed and treated. In Japan, high-grade cervical precancer (CIN3) is the standard threshold for immediate treatment. Cytology read as HSIL or ASC-H is more likely to reflect histological CIN3 than cytology read as LSIL. However, the risk of CIN3 diagnosed at initial colposcopy and biopsy is 4-10 %, even for women with LSIL cytology. Referring cytology-positive women for colposcopy and biopsy is warranted to eliminate the possibility of CIN3+ lesions because of the limited risk stratification provided by cytology.
In this study, addition of genotype-specific or carcinogenic HPV testing to cytological testing enabled additional, more precise, risk stratification for women referred for colposcopy than did cytology alone (Fig. 1 ). For women with LSIL cytology, the absolute risk of CIN3+ biopsy results was 0.0 % (95 % CI 0.0-4.2) for those who tested negative for the eight highest-risk HPV types (HPV16/18/31/33/35/45/52/58), suggesting that these women might not need immediate colposcopy referral. A prospective cohort study of Japanese women with LSIL demonstrated that women with LSIL who tested negative for these eight highest-risk HPV types had a high likelihood (>50 %) of regression to normal cytology within 1 year and a very low risk (only 1.7 %) of progression to CIN3+ within the next 5 years [13] . This observation also supports delayed colposcopy for women with LSIL who test negative for the eight types. In this study, 41.1 % of women referred for colposcopy for LSIL cytology were negative for the eight major carcinogenic HPV types. Therefore, testing LSIL cases for the eight HPV types as a triage test for colposcopy referral may reduce the number of colposcopy referrals by approximately 40 %. In this study, women with LSIL cytology were more likely to have CIN3+ histology (11.7 %) than in the ALTS and ATHENA trials (5.6 and 4.4 %, respectively) [4, 5] , implying that the prevalence of the eight highest-risk HPV types may have been higher in our study subjects. Accordingly, incorporating this triage test into the clinical management of women with LSIL cytology might reduce the number of colposcopy referrals by a greater percentage than estimated in this study. Although women negative for the 13 high-risk HPVs were also at very low risk of CIN3+ histology [13] , tests for high-risk HPV detecting all 13 types are unlikely to serve as an efficient tool for triaging LSIL cases for colposcopy; the number of colposcopy referrals would be reduced by only 20-30 % because of the high prevalence (70-80 %) of the 13 carcinogenic HPVs among women with LSIL cytology [4, 5] . Cost-utility analysis would be needed for incorporation of HPV genotyping assays into clinical practice as a triage test of women with LSIL cytology. Only 4-10 % of women with LSIL are diagnosed with CIN3+ [4, 5] . In Japan, therefore, >90 % of women with LSIL are usually followed up without immediate treatment after colposcopy, because CIN3 is the standard threshold for immediate treatment [3] . The current JSOG and JAOG guidelines already recommend HPV genotyping assays for assessment of a woman's subsequent risk of progression to CIN3 "after" colposcopy [3] . HPV genotyping assays "before" colposcopy are likely to reduce unnecessary colposcopy referrals and painful biopsies by approximately 40 %, thus avoiding potential overtreatment of non-progressive lesions. Although HPV genotyping assays approved for clinical practice in Japan, for example the Clinichip HPV ® test and the Mebgen HPV™ kit (Medical and Biological Laboratories, Nagoya, Japan), are currently expensive (20,000 JPY), colposcopy and diagnostic biopsies are similarly expensive (17,600 JPY including histological assessment of diagnostic biopsies). Development of less expensive HPV detection assays distinguishing the eight major carcinogenic HPV genotypes would achieve greater medical cost savings.
In contrast, HPV genotyping assays for women with a raised threshold of abnormal cytology (HSIL/ASC-H) would be of little benefit as a triage test to identify populations at low risk who do not need immediate colposcopy and biopsy. The CIN3+ risk was extremely high (67.9 %) for women with HPV16/18-positive HSIL/ASC-H. However, women with HPV16/18-negative HSIL/ASC-H were still at 48.2 % risk of CIN3+. As a triage test to identify CIN3+ among women with HSIL/ASC-H cytology, detection of the 8 or 13 types was still equivalent to detection of HPV16/18 as indicative of a high risk of CIN3+ among test-negative women. Even when the HPV detection assay for the eight types or more was used as a triage test for colposcopy, the risk of CIN3+ among women with negative test results remained largely unchanged (>35 %; Table 3 ), and remained above the level widely regarded the threshold for colposcopy referral. These findings suggest that women with HSIL/ASC-H cytology cannot avoid immediate colposcopy and biopsy to eliminate the possibility of the presence of CIN3+ lesions, irrespective of HPV genotyping results.
CIN3 is almost invariably caused by high-risk HPVs. However, in this study, seven (4.8 %) of 145 women diagnosed with CIN3 were negative for the 13 high-risk HPVs. In large-scale clinical trials, a small percentage of cases with CIN3 histology have been reported to be negative for high-risk HPV DNA (5.6 % at enrollment of the immediate colposcopy arm in ALTS and 7.9 % in ATHENA) [6, 18] . One possible explanation is that these high-risk HPV-negative CIN3 lesions may be a result of misclassified histology (classified incorrectly as CIN3), non-high-risk HPV, or false-negative high-risk HPV. Cervical specimens from these patients were diagnosed as CIN3 both by pathologists at local hospitals and by central pathology reviewers. When an L1-PCR HPV assay was used to detect at least 26 genital HPVs, these CIN3 cases were also HPV DNA-negative (data not shown). Therefore, simple sampling errors were more likely. These high-risk HPV-negative CIN3 cases were all diagnosed after HSIL cytology was observed. These results also emphasize that immediate colposcopy is needed for women with HSIL/ASC-H cytology, because HSIL/ASC-H cytology itself confers a substantially high risk of CIN3+, irrespective of HPV testing results. In US cervical screening guidelines on co-testing of cytology and high-risk HPV testing, colposcopy is recommended not only for women with HPV-positive HSIL/ASC-H but also for those with HPV-negative HSIL/ASC-H [1] .
Although our data suggested the usefulness of HPV genotyping assays as a triage test of women with LSIL cytology, concerns about patient safety may be raised. For instance, one may speculate that misclassified HSIL/ ASC-H cytology (classified incorrectly as LSIL cytology) may increase a risk of missed CIN3. In this study, we did not review referral cytology because of the relevance to clinical practice. However, in our previous study using central review, misclassification of HSIL/ASC-H cytology was observed for 3.8 % of women with a community interpretation of LSIL cytology [13] . Furthermore, most (>85 %) of these women with misclassified HSIL/ASC-H cytology would be sent for colposcopy and biopsy because of positive triage test results. Therefore, the estimated percentage of women that may miss necessary colposcopy and biopsy would be low (<0.6 %). Another concern is that follow-up of women with histologically unconfirmed LSIL smears (potentially including CIN2) may not be safe. However, a prospective cohort study of Japanese women with LSIL has demonstrated that the risk of CIN3 diagnosed during 2-year follow-up is 2.0 %, even among women with biopsy-positive CIN2, if they are negative for the eight types HPV16/18/31/33/35/45/52/58 [13] . This risk was lower than that (5.6 %) for women with LSIL cytology in the immediate colposcopy group of the ALTS trial [4] .
High population coverage with effective HPV vaccines may affect the usefulness of the HPV genotyping assay as a triage test of women with LSIL cytology. In Australia, HPV vaccination programs have resulted in significant reduction of genital warts and high-grade CIN among young women [19] . As HPV vaccination increases, cervical cancer and precancer (CIN3) will become rare and almost all abnormal cytological results will be indicative of ASC-US or LSIL cytology. Furthermore, evidence from the US and Scotland has demonstrated that HPV type-specific prevalence differs significantly between vaccinated and unvaccinated populations [20, 21] . Accordingly, we will need to reevaluate use of type-specific or carcinogenic HPV testing in the post-vaccination era. To monitor the effect of HPV vaccination on genotype-specific prevalence in Japan, a multicenter epidemiological study (MINT study) is now in progress [22] .
In conclusion, testing for the eight highest-risk HPV types will be clinically useful as a triage test for immediate colposcopy and biopsy for women with LSIL cytology but not for women with HSIL/ASC-H. Addition of this triage test to clinical management for women with LSIL cytology may reduce the number of referrals for colposcopy by 40-50 %. However, the sample size in this study was small; further prospective studies with large sample sizes will therefore be needed to confirm our results.
